|
Jan 25, 2022
|
FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
- RAINBOWFISH study interim results showed that after treatment with Evrysdi pre-symptomatic infants with spinal muscular atrophy achieved same motor milestones as healthy infants - SOUTH PLAINFIELD, N.J. , Jan. 25, 2022 /PRNewswire/ -- PTC Therapeutics, Inc.
|
|
|
Jan 18, 2022
|
PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
- 2022 grant program will focus on Innovation and Transition to Adulthood initiatives - - Submissions due on March 18, 2022 - SOUTH PLAINFIELD, N.J. , Jan. 18, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the eighth annual STRIVE ™ awards program for
|
|
|
Jan 13, 2022
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 7, 2022 , the company approved non-statutory stock options to purchase an aggregate of 18,255 shares of its common stock and 10,675 restricted stock units ("RSUs"), each
|
|
|
Jan 13, 2022
|
PTC Therapeutics Announces Launch of 2022 Global Talent Pipeline Program
- One-year fellowship provides diverse work experiences across PTC's business areas - SOUTH PLAINFIELD, N.J. , Jan. 13, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the company's 2022 Talent Pipeline Program, a one-year, global initiative designed to
|
|
|
Jan 10, 2022
|
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 40th Annual J.P. Morgan Healthcare Conference
- $536 million unaudited 2021 total revenue representing impressive 41% year-over-year growth - - $700 - 750 million 2022 total revenue guidance - - Results are expected in four registration-directed trials this year - - Three additional registration-directed clinical trials expected to initiate in
|
|
|
Jan 04, 2022
|
Waylivra™ Receives Innovative Drug Category Pricing to Treat Familial Chylomicronemia Syndrome in Brazil
- Additional application submitted to ANVISA for a new indication to treat familial partial lipodystrophy - SOUTH PLAINFIELD, N.J. , Jan. 4, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Waylivra™ (volanesorsen) has successfully received Category 1 classification
|
|
|
Jan 03, 2022
|
PTC Therapeutics to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
SOUTH PLAINFIELD, N.J. , Jan. 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the 40 th Annual J.P. Morgan Virtual Healthcare Conference on Monday, Jan. 10 , at 7:30 a.m. EST .
|
|
|
Dec 20, 2021
|
Oral Splicing Modifiers that Systemically Lower Huntington Disease Protein Discovered Through PTC Therapeutics' Innovative Splicing Platform
-- Results published in Nature Communications -- -- Description of novel splicing mechanism causing inhibition of HTT gene expression -- SOUTH PLAINFIELD, N.J. , Dec. 20, 2021 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced the Nature Communications publication characterizing
|
|
|
Dec 06, 2021
|
Evrysdi® Distinguished by Two Prestigious Awards for Outstanding Innovation in Drug Discovery
SOUTH PLAINFIELD, N.J. , Dec. 6, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi ® (risdiplam) has received multiple awards that recognize it as one of the most innovative therapies of 2021 and for its life-saving impact.
|
|
|
Dec 02, 2021
|
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH PLAINFIELD, N.J. , Dec. 2, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 29, 2021 , the company approved non-statutory stock options to purchase an aggregate of 83,750 shares of its common stock and 21,550 restricted stock units ("RSUs"), each
|
|
